287 related articles for article (PubMed ID: 18602024)
21. Emerging PEGylated drugs.
Kang JS; Deluca PP; Lee KC
Expert Opin Emerg Drugs; 2009 Jun; 14(2):363-80. PubMed ID: 19453284
[TBL] [Abstract][Full Text] [Related]
22. Proteochemometrics mapping of the interaction space for retroviral proteases and their substrates.
Kontijevskis A; Petrovska R; Yahorava S; Komorowski J; Wikberg JE
Bioorg Med Chem; 2009 Jul; 17(14):5229-37. PubMed ID: 19539482
[TBL] [Abstract][Full Text] [Related]
23. Peptides and peptide conjugates: therapeutics on the upward path.
Ahrens VM; Bellmann-Sickert K; Beck-Sickinger AG
Future Med Chem; 2012 Aug; 4(12):1567-86. PubMed ID: 22917246
[TBL] [Abstract][Full Text] [Related]
24. Efficient degradation-aided selection of protease inhibitors by phage display.
Hawinkels LJ; van Rossenberg SM; de Jonge-Muller ES; Molenaar TJ; Appeldoorn CC; van Berkel TJ; Sier CF; Biessen EA
Biochem Biophys Res Commun; 2007 Dec; 364(3):549-55. PubMed ID: 17959143
[TBL] [Abstract][Full Text] [Related]
25. Engineered protein scaffolds as next-generation antibody therapeutics.
Gebauer M; Skerra A
Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
[TBL] [Abstract][Full Text] [Related]
26. Commercial proteases: present and future.
Li Q; Yi L; Marek P; Iverson BL
FEBS Lett; 2013 Apr; 587(8):1155-63. PubMed ID: 23318711
[TBL] [Abstract][Full Text] [Related]
27. Resistance to dermcidin-derived peptides is independent of bacterial protease activity.
Senyürek I; Döring G; Kalbacher H; Deeg M; Peschel A; Wolz C; Schittek B
Int J Antimicrob Agents; 2009 Jul; 34(1):86-90. PubMed ID: 19201578
[TBL] [Abstract][Full Text] [Related]
28. Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies.
Kessel C; Kreuz W; Klich K; Becker-Peters K; Vorpahl F; Dietrich U; Klingebiel T; Königs C
ChemMedChem; 2009 Aug; 4(8):1364-70. PubMed ID: 19533722
[TBL] [Abstract][Full Text] [Related]
29. Detergent proteases.
Maurer KH
Curr Opin Biotechnol; 2004 Aug; 15(4):330-4. PubMed ID: 15296930
[TBL] [Abstract][Full Text] [Related]
30. Strategies to improve plasma half life time of peptide and protein drugs.
Werle M; Bernkop-Schnürch A
Amino Acids; 2006 Jun; 30(4):351-67. PubMed ID: 16622600
[TBL] [Abstract][Full Text] [Related]
31. Proteases' prime targets revealed.
Diamond SL; Greenbaum D
Nat Biotechnol; 2008 Jun; 26(6):652-3. PubMed ID: 18536687
[No Abstract] [Full Text] [Related]
32. Peptide-based drug design: here and now.
Otvos L
Methods Mol Biol; 2008; 494():1-8. PubMed ID: 18726565
[TBL] [Abstract][Full Text] [Related]
33. Peptide-based delivery to bone.
Aoki K; Alles N; Soysa N; Ohya K
Adv Drug Deliv Rev; 2012 Sep; 64(12):1220-38. PubMed ID: 22709649
[TBL] [Abstract][Full Text] [Related]
34. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators.
Dimasi N; Gao C; Fleming R; Woods RM; Yao XT; Shirinian L; Kiener PA; Wu H
J Mol Biol; 2009 Oct; 393(3):672-92. PubMed ID: 19699208
[TBL] [Abstract][Full Text] [Related]
35. Development of peptides specifically modulating the activity of KLK2 and KLK3.
Koistinen H; Närvänen A; Pakkala M; Hekim C; Mattsson JM; Zhu L; Laakkonen P; Stenman UH
Biol Chem; 2008 Jun; 389(6):633-42. PubMed ID: 18627344
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides.
Raucher D; Moktan S; Massodi I; Bidwell GL
Expert Opin Drug Deliv; 2009 Oct; 6(10):1049-64. PubMed ID: 19743895
[TBL] [Abstract][Full Text] [Related]
37. "Reverse degradomics", monitoring of proteolytic trimming by multi-CE and confocal detection of fluorescent substrates and reaction products.
Piccard H; Hu J; Fiten P; Proost P; Martens E; Van den Steen PE; Van Damme J; Opdenakker G
Electrophoresis; 2009 Jul; 30(13):2366-77. PubMed ID: 19621364
[TBL] [Abstract][Full Text] [Related]
38. De novo identification of binding sequences for antibody replacement molecules.
Quirk S; Zhong S; Hernandez R
Proteins; 2009 Aug; 76(3):693-705. PubMed ID: 19274738
[TBL] [Abstract][Full Text] [Related]
39. Exploring peptide-likeness of active molecules using 2D fingerprint methods.
Eckert H; Bajorath J
J Chem Inf Model; 2007; 47(4):1366-78. PubMed ID: 17539624
[TBL] [Abstract][Full Text] [Related]
40. Modulating the pharmacokinetics of therapeutic antibodies.
Constantinou A; Chen C; Deonarain MP
Biotechnol Lett; 2010 May; 32(5):609-22. PubMed ID: 20131077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
